Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes

Clinical Breast Cancer

Volumn 6, Issue 2, 2005, Pages 158-162

  Andres, Raquel ^a   Mayordomo, Jose Ignacio ^a   Lara, Ricardo ^a   Lastra, Rodrigo ^a   Ortega, Eugenia ^a   Polo, Eduardo ^a   Lambea, Julio ^a   Isla, Dolores ^a   Saenz Cusi, Alberto ^a   Escudero, Pilar ^a   Tres, Alejandro ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Combination therapy; Hand foot syndrome; Pyridoxine; Pyrimidine

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MITOXANTRONE; NAVELBINE; ONDANSETRON; PYRIDOXINE; PYRIMIDINE NUCLEOTIDE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; METASTASIS POTENTIAL; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROTEIN METABOLISM; STEM CELL TRANSPLANTATION; STOMATITIS; THROMBOCYTOPENIA;

EID: 22144472229     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.018     Document Type: Article

References (14)

1. Jemal A, Murray T, Ward A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Miwa M, Ura M, Nishida M, et al. Desing of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissues. Eur J Cancer 1998; 34:1274-1281.
3. Blum JL, Jones SE, Buzdar AU. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer patients. J Clin Oncol 1999; 17:485-493.
4. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer 2001; 92:1759-1768.
5. )) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14:1227-1233.
6. Sawada N, Fujimoto-Ouchi K, Ishikawa T. Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 2002; 43:1088a (Abstract #5388).
7. Hess V, Salzberg M, Borner M, et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 2003; 21:66-68.
8. Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly high-dose gemeitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003; 14:97-104.
9. Miller AB, Hoogstraten B, Statquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214
10. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10:239-253.
11. Schilsky RL, Bertucci D, Vogelzang NJ, et al. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 2002; 20:582-587.
12. Hidalgo M, Castellano D, Paz-Ares L, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17:585-592.
13. Seidman AD, O'Shaughnessy J, Misset JL. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002; 7(suppl 6):20-28.
14. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.